Do analysts recommend SVA or MDWD?

MediWound has a consensus price target of $33.00, indicating a potential upside of 149.81%. Given MediWound's stronger consensus rating and higher probable upside, analysts plainly believe MediWound is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MediWound 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger valuation and earnings, SVA or MDWD?

MediWound has lower revenue, but higher earnings than Sinovac Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A MediWound $16.96M 10.01 -$23.88M -$1.80 N/A

Does the media favor MDWD or SGMT?

In the previous week, MediWound had 1 more articles in the media than Sagimet Biosciences. MarketBeat recorded 6 mentions for MediWound and 5 mentions for Sagimet Biosciences. MediWound's average media sentiment score of 0.37 beat Sagimet Biosciences' score of 0.26 indicating that MediWound is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediWound 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sagimet Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, RGNX or MDWD?

MediWound has lower revenue, but higher earnings than REGENXBIO. MediWound is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio REGENXBIO $170.44M 3.56 -$193.88M -$3.79 N/A MediWound $16.96M 10.01 -$23.88M -$1.80 N/A

Is RGNX or MDWD more profitable?

REGENXBIO has a net margin of -112.58% compared to MediWound's net margin of -170.10%. MediWound's return on equity of -47.24% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets REGENXBIO -112.58% -220.07% -46.04% MediWound -170.10% -47.24% -24.27%

Does the media prefer RGNX or MDWD?

In the previous week, REGENXBIO had 1 more articles in the media than MediWound. MarketBeat recorded 7 mentions for REGENXBIO and 6 mentions for MediWound. REGENXBIO's average media sentiment score of 0.69 beat MediWound's score of 0.37 indicating that REGENXBIO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediWound 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AUTL or MDWD?

In the previous week, MediWound had 3 more articles in the media than Autolus Therapeutics. MarketBeat recorded 6 mentions for MediWound and 3 mentions for Autolus Therapeutics. MediWound's average media sentiment score of 0.37 beat Autolus Therapeutics' score of 0.00 indicating that MediWound is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MediWound 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer MDWD or AVTE?

MediWound currently has a consensus target price of $33.00, indicating a potential upside of 149.81%. Given MediWound's stronger consensus rating and higher probable upside, analysts plainly believe MediWound is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediWound 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

MediWound (MDWD) Competitors

$13.21 +0.15 (+1.15%)

As of 09/3/2026 04:00 PM Eastern

Compare

MDWD vs. SVA, SGMT, RGNX, AUTL, and AVTE

Should you buy MediWound stock or one of its competitors? MediWound's main competitors and comparable companies include Sinovac Biotech (SVA), Sagimet Biosciences (SGMT), REGENXBIO (RGNX), Autolus Therapeutics (AUTL), and Aerovate Therapeutics (AVTE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MediWound compare to Sinovac Biotech?

Sinovac Biotech (NASDAQ:SVA) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

MediWound has a consensus price target of $33.00, indicating a potential upside of 149.81%. Given MediWound's stronger consensus rating and higher probable upside, analysts plainly believe MediWound is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, MediWound had 6 more articles in the media than Sinovac Biotech. MarketBeat recorded 6 mentions for MediWound and 0 mentions for Sinovac Biotech. MediWound's average media sentiment score of 0.37 beat Sinovac Biotech's score of 0.00 indicating that MediWound is being referred to more favorably in the news media.

Company	Overall Sentiment
Sinovac Biotech	Neutral
MediWound	Neutral

Sinovac Biotech has a net margin of 0.00% compared to MediWound's net margin of -170.10%. Sinovac Biotech's return on equity of 0.00% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
MediWound	-170.10%	-47.24%	-24.27%

46.8% of MediWound shares are owned by institutional investors. 12.8% of Sinovac Biotech shares are owned by insiders. Comparatively, 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Sinovac Biotech has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, MediWound has a beta of 0.14, indicating that its share price is 86% less volatile than the broader market.

MediWound has lower revenue, but higher earnings than Sinovac Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A
MediWound	$16.96M	10.01	-$23.88M	-$1.80	N/A

Summary

MediWound beats Sinovac Biotech on 8 of the 14 factors compared between the two stocks.

How does MediWound compare to Sagimet Biosciences?

MediWound (NASDAQ:MDWD) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

MediWound currently has a consensus target price of $33.00, suggesting a potential upside of 149.81%. Sagimet Biosciences has a consensus target price of $29.17, suggesting a potential upside of 167.09%. Given Sagimet Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Sagimet Biosciences is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, MediWound had 1 more articles in the media than Sagimet Biosciences. MarketBeat recorded 6 mentions for MediWound and 5 mentions for Sagimet Biosciences. MediWound's average media sentiment score of 0.37 beat Sagimet Biosciences' score of 0.26 indicating that MediWound is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediWound	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sagimet Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sagimet Biosciences has a net margin of 0.00% compared to MediWound's net margin of -170.10%. Sagimet Biosciences' return on equity of -31.96% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-170.10%	-47.24%	-24.27%
Sagimet Biosciences	N/A	-31.96%	-30.57%

46.8% of MediWound shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 9.2% of MediWound shares are owned by company insiders. Comparatively, 11.5% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

MediWound has a beta of 0.14, meaning that its share price is 86% less volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.45, meaning that its share price is 245% more volatile than the broader market.

MediWound has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	10.01	-$23.88M	-$1.80	N/A
Sagimet Biosciences	$2M	339.39	-$51.04M	-$1.28	N/A

Summary

Sagimet Biosciences beats MediWound on 10 of the 16 factors compared between the two stocks.

How does MediWound compare to REGENXBIO?

REGENXBIO (NASDAQ:RGNX) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

REGENXBIO has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, MediWound has a beta of 0.14, suggesting that its share price is 86% less volatile than the broader market.

MediWound has lower revenue, but higher earnings than REGENXBIO. MediWound is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	3.56	-$193.88M	-$3.79	N/A
MediWound	$16.96M	10.01	-$23.88M	-$1.80	N/A

In the previous week, REGENXBIO had 1 more articles in the media than MediWound. MarketBeat recorded 7 mentions for REGENXBIO and 6 mentions for MediWound. REGENXBIO's average media sentiment score of 0.69 beat MediWound's score of 0.37 indicating that REGENXBIO is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediWound	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

REGENXBIO has a net margin of -112.58% compared to MediWound's net margin of -170.10%. MediWound's return on equity of -47.24% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-112.58%	-220.07%	-46.04%
MediWound	-170.10%	-47.24%	-24.27%

88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by insiders. Comparatively, 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

REGENXBIO presently has a consensus target price of $23.27, suggesting a potential upside of 152.96%. MediWound has a consensus target price of $33.00, suggesting a potential upside of 149.81%. Given REGENXBIO's stronger consensus rating and higher possible upside, research analysts plainly believe REGENXBIO is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

REGENXBIO beats MediWound on 11 of the 16 factors compared between the two stocks.

How does MediWound compare to Autolus Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

In the previous week, MediWound had 3 more articles in the media than Autolus Therapeutics. MarketBeat recorded 6 mentions for MediWound and 3 mentions for Autolus Therapeutics. MediWound's average media sentiment score of 0.37 beat Autolus Therapeutics' score of 0.00 indicating that MediWound is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MediWound	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MediWound has a net margin of -170.10% compared to Autolus Therapeutics' net margin of -238.66%. MediWound's return on equity of -47.24% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-238.66%	-178.66%	-49.34%
MediWound	-170.10%	-47.24%	-24.27%

Autolus Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 336.68%. MediWound has a consensus target price of $33.00, indicating a potential upside of 149.81%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Autolus Therapeutics is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Autolus Therapeutics has a beta of 2.1, suggesting that its stock price is 110% more volatile than the broader market. Comparatively, MediWound has a beta of 0.14, suggesting that its stock price is 86% less volatile than the broader market.

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 9.2% of MediWound shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

MediWound has lower revenue, but higher earnings than Autolus Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	8.08	-$287.53M	-$1.06	N/A
MediWound	$16.96M	10.01	-$23.88M	-$1.80	N/A

Summary

Autolus Therapeutics beats MediWound on 10 of the 17 factors compared between the two stocks.

How does MediWound compare to Aerovate Therapeutics?

MediWound (NASDAQ:MDWD) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Aerovate Therapeutics has a net margin of 0.00% compared to MediWound's net margin of -170.10%. MediWound's return on equity of -47.24% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-170.10%	-47.24%	-24.27%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

MediWound has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	10.01	-$23.88M	-$1.80	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

46.8% of MediWound shares are held by institutional investors. 9.2% of MediWound shares are held by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

MediWound has a beta of 0.14, suggesting that its stock price is 86% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

MediWound currently has a consensus target price of $33.00, indicating a potential upside of 149.81%. Given MediWound's stronger consensus rating and higher probable upside, analysts plainly believe MediWound is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, MediWound had 6 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 6 mentions for MediWound and 0 mentions for Aerovate Therapeutics. MediWound's average media sentiment score of 0.37 beat Aerovate Therapeutics' score of 0.00 indicating that MediWound is being referred to more favorably in the media.

Company	Overall Sentiment
MediWound	Neutral
Aerovate Therapeutics	Neutral

Summary

MediWound beats Aerovate Therapeutics on 10 of the 15 factors compared between the two stocks.

Get MediWound News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDWD vs. The Competition

Export

Metric	MediWound	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$167.85M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-7.34	12.66	273.28	25.38
Price / Sales	10.01	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	4.77	16.29	12.89	6.14
Net Income	-$23.88M	-$22.72M	$3.47B	$349.01M
7 Day Performance	4.34%	0.34%	0.61%	-0.27%
1 Month Performance	-7.62%	8.52%	5.73%	0.68%
1 Year Performance	-21.18%	52.66%	25.37%	14.84%

MediWound Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDWD MediWound	2.0579 of 5 stars	$13.21 +1.1%	$33.00 +149.8%	-20.3%	$167.85M	$16.96M	N/A	80
SVA Sinovac Biotech	N/A	$6.47 flat	N/A	N/A	$644.66M	$386.01M	N/A	3,008	High Trading Volume
SGMT Sagimet Biosciences	3.1568 of 5 stars	$10.50 +2.3%	$29.17 +177.8%	+48.8%	$637.75M	$2M	N/A	8	Gap Up
RGNX REGENXBIO	2.9343 of 5 stars	$9.32 -1.9%	$23.27 +149.7%	-6.7%	$627.12M	$174.48M	N/A	370
AUTL Autolus Therapeutics	2.96 of 5 stars	$2.31 -1.7%	$10.00 +332.9%	+59.0%	$625.48M	$75.39M	N/A	330

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDWD) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MediWound (MDWD) Competitors

MDWD vs. SVA, SGMT, RGNX, AUTL, and AVTE

How does MediWound compare to Sinovac Biotech?

Summary

How does MediWound compare to Sagimet Biosciences?

Summary

How does MediWound compare to REGENXBIO?

Summary

How does MediWound compare to Autolus Therapeutics?

Summary

How does MediWound compare to Aerovate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD vs. The Competition

MediWound Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MediWound (MDWD) Competitors

MDWD vs. SVA, SGMT, RGNX, AUTL, and AVTE

How does MediWound compare to Sinovac Biotech?

Do analysts recommend SVA or MDWD?

Does the media prefer SVA or MDWD?

Is SVA or MDWD more profitable?

Do institutionals and insiders believe in SVA or MDWD?

Which has more volatility & risk, SVA or MDWD?

Which has stronger valuation and earnings, SVA or MDWD?

Summary

How does MediWound compare to Sagimet Biosciences?

Do analysts rate MDWD or SGMT?

Does the media favor MDWD or SGMT?

Is MDWD or SGMT more profitable?

Do insiders and institutionals have more ownership in MDWD or SGMT?

Which has more risk & volatility, MDWD or SGMT?

Which has higher earnings and valuation, MDWD or SGMT?

Summary

How does MediWound compare to REGENXBIO?

Which has more risk and volatility, RGNX or MDWD?

Which has higher valuation & earnings, RGNX or MDWD?

Does the media prefer RGNX or MDWD?

Is RGNX or MDWD more profitable?

Do institutionals and insiders hold more shares of RGNX or MDWD?

Do analysts rate RGNX or MDWD?

Summary

How does MediWound compare to Autolus Therapeutics?

Does the media favor AUTL or MDWD?

Is AUTL or MDWD more profitable?

Do analysts rate AUTL or MDWD?

Which has more risk and volatility, AUTL or MDWD?

Do institutionals and insiders believe in AUTL or MDWD?

Which has better earnings and valuation, AUTL or MDWD?

Summary

How does MediWound compare to Aerovate Therapeutics?

Is MDWD or AVTE more profitable?

Which has preferable earnings & valuation, MDWD or AVTE?

Do institutionals & insiders hold more shares of MDWD or AVTE?

Which has more risk and volatility, MDWD or AVTE?

Do analysts prefer MDWD or AVTE?

Does the media refer more to MDWD or AVTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD vs. The Competition

MediWound Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools